611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Women's Health
Basic InformationLatest News
Mom's Weight-Loss Surgery Lowers Many Pregnancy Complications, Raises OthersPregnant Women Need to Take Care in Sweltering Summer HeatAre Antibiotics Really the Answer for UTIs in Women?Stronger Hearts, Better Outcomes in Pregnancy: StudyCould Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Screening Often Misses Endometrial Cancer in Black WomenAHA News: Pregnant Mom's Diet May Influence Baby's Cardiovascular HealthPandemic Delays in Screening Mean More Breast Cancer Deaths Ahead: StudyUrinary Incontinence Can Affect a Woman's Mental HealthCOVID Vaccine Doesn't Infiltrate Breast MilkGap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by EnoughCost a Barrier to Cervical Cancer Screening for Many U.S. WomenAlcohol Still a Threat in Too Many American Pregnancies: StudyWomen's Cancer Screenings Plummeted During PandemicPandemic Day Care Closures Forced 600,000 U.S. Working Moms to Leave JobsNo Sign Prior COVID Infection Affects a Woman's Fertility: StudyFertility Drugs Won't Raise Breast Cancer RiskMigraines Tied to Higher Odds for Complications in PregnancyWomen, Take These Key Steps to Good Urological HealthAre Women Absorbing Toxins From Their Makeup?Race Doesn't Affect Risk for Genes That Raise Breast Cancer RiskHealthy Levels of Vitamin D May Boost Breast Cancer OutcomesHeavy Drinking Could Lower a Woman's Odds of ConceptionAHA News: Asian and Pacific Islander Women May Be at Greatest Risk for Preeclampsia ComplicationsFibroid Pain, Bleeding Is Driving Thousands of Women to the ERA Woman's Diet Might Help Her Avoid Breast CancerBreast Cancer's Spread Is More Likely in Black Women, Study FindsDrug Lynparza Could Help Fight Some Early-Stage Breast CancersAHA News: Menopause Before 40 Tied to Higher Stroke RiskHealthy Eating Lowers Pregnancy Complication RiskAortic Tears Are Even More Deadly for Women, Study FindsFDA Warns of Bogus Fertility Claims for Some SupplementsAHA News: Surprisingly Few Women May Have Good Heart Health Before PregnancyOsteoporosis Might Also Raise a Woman's Odds for Hearing LossModerate Use of Hair Relaxers Won't Raise Black Women's Cancer Risk: StudyMammography Rates Plummeted During Pandemic'Yo-Yo' Dieting May Mean Sleepless Nights for WomenGluten Doesn't Trigger 'Brain Fog' for Women Without Celiac Disease: StudyHPV Vaccination Is Lowering U.S. Cervical Cancer RatesSmoggy Air Might Raise Black Women's Odds for FibroidsAHA News: Preterm Deliveries May Pose Long-Term Stroke Risk for MothersWomen Get Help Later Than Men When Heart Attack StrikesLots of Sugary Drinks Doubles Younger Women's Colon Cancer Risk: StudyHeart Risk Factors Show Up Earlier in U.S. Black WomenBetter Access to Birth Control Boosts School Graduation RatesA Vitamin Could Be Key to Women's Pain After Knee ReplacementFreezing Tumors Could Be New Treatment for Low-Risk Breast CancersGiving Birth During the Pandemic? Facts You Need to KnowDo Your Genes Set You Up for Hot Flashes?Common Complication of Pregnancy Tied to Higher Stroke Risk Later
Questions and AnswersLinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Wellness and Personal Development
Mental Disorders

Drug Lynparza Could Help Fight Some Early-Stage Breast Cancers

HealthDay News
by By Dennis Thompson HealthDay Reporter
Updated: Jun 4th 2021

new article illustration

FRIDAY, June 4, 2021 (HealthDay News) -- A twice-daily pill can dramatically reduce the risk of breast cancer recurrence in women who are genetically prone to the disease, researchers report.

The pill — olaparib (Lynparza) — works by blocking a natural enzyme called PARP that normally fixes DNA damage in healthy cells, but in these women actually promotes the growth of cancerous cells.

Early high-risk breast cancer patients taking olaparib for a year had a 42% reduced risk of cancer recurrence or death compared to those given a placebo, said lead researcher Dr. Andrew Tutt, director of the Breast Cancer Now Toby Robins Research Center at the Institute of Cancer Research in London.

"Patients who received olaparib after surgery and chemotherapy were more likely to be alive without cancer and avoid metastasis than the patients who received placebo," he said.

These results were presented Thursday at an online meeting of the American Society of Clinical Oncology. Findings presented at meetings should be considered preliminary until published in a peer-reviewed journal.

Olaparib already is approved to treat patients with metastatic breast cancer who have mutations in the BRCA1 or BRCA2 genes. These genes typically suppress cancer, but mutations actually increase cancer risk for some people.

About 5% of breast cancers are associated with BRCA1 or BRCA2 mutations, Tutt noted.

Breast cancers that occur due to BRCA1 or BRCA2 mutations rely on the PARP enzyme to remain alive, grow and divide. Drugs called PARP inhibitors take advantage of this fact to block the enzyme and prevent the cancer from coming back.

In this clinical trial, more than 1,800 patients with stage 2 to 3 breast cancers treated with surgery and chemotherapy were randomly assigned to take either 300 milligrams of olaparib or a placebo twice a day for a year.

Patients on olaparib had a three-year invasive disease-free survival rate — no recurring breast cancer or other new cancers — of about 86%, compared with 77% for those taking a placebo, the findings showed.

Dr. Amy Tiersten is a professor of hematology and medical oncology with the Icahn School of Medicine at Mount Sinai in New York City. She said, "We have already known for some time that PARP inhibitors have activity in patients with metastatic breast cancer, but this is the first time we have seen efficacy in the early-stage setting. This study showed a substantial reduction in the risk of recurrence in this population and, therefore, the potential to cure more patients with BRCA-associated early breast cancer."

Side effects were consistent with previous studies of olaparib, Tutt said. The most serious common side effects included anemia, lower white blood cell counts and fatigue.

Tutt said the study shows the importance of performing genetic testing on cancer patients, to look for traits and mutations that could be exploited to improve treatment and survival.

"There certainly is a case for a mindset change in the community around where we use germline genetic testing," Tutt said. "We've classically thought about it as something to do to determine someone's risk of the disease and inform perhaps other members of their family if they've already had it."

Instead of just assessing risk, this genetic information can be used to save lives, Tutt noted.

Dr. Lori Pierce, president of the American Society of Clinical Oncology, agreed.

"This further highlights the importance of genetic testing in appropriate patients so that we know which patients will benefit from this therapy," Pierce said. "I think it may even open the door to additional trials of adjuvant PARP inhibitors for other BRCA1- and 2-associated cancers."

Olaparib can be a pricey drug. The cost for a supply of sixty 100-milligram tablets is a little more than $7,500, according to Drugs.com.

More information

Dana-Farber Cancer Institute has more about PARP inhibitors.

SOURCES: Andrew Tutt, MBChB, PhD, director, Breast Cancer Now Toby Robins Research Center, Institute of Cancer Research, London; Lori Pierce, MD, president, American Society of Clinical Oncology, Alexandria, Va.; Amy Tiersten, MD, professor, hematology and medical oncology, Icahn School of Medicine at Mount Sinai, New York City; presentation, American Society of Clinical Oncology, June 3, 2021, online